Biocon, India's pre-eminent biotech company, is planning to spin out its in-house CRO in an Indian IPO, a move that shines a light on the country's evolving industry. As FiercePharmaAsia's EJ Lane notes, Biocon's Syngene is coming off a record revenue quarter on the way to its IPO, and a major success could change how investors in the country look at the biomedical sector. More